Beyfortus nirsevimab RSV
Selected indexed studies
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. (N Engl J Med, 2022) [PMID:35235726]
- Analysis of Beyfortus(®) (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention. (Curr Issues Mol Biol, 2024) [PMID:39329969]
- Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. (N Engl J Med, 2023) [PMID:38157500]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nirsevimab: A Review. (2024) pubmed
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. (2022) pubmed
- Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. (2023) pubmed
- Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. (2020) pubmed
- Nirsevimab and Hospitalization for RSV Bronchiolitis. (2024) pubmed
- RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing. (2024) pubmed
- Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. (2022) pubmed
- Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. (2023) pubmed
- Analysis of Beyfortus(®) (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention. (2024) pubmed
- Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants. (2025) pubmed